Ajanta Pharma launches Eletriptan Hydrobromide Tablets in US market

31 Aug 2017 Evaluate

Ajanta Pharma has launched Eletriptan Hydrobromide Tablets in the US market through its wholly owned subsidiary Ajanta Pharma USA. It is a bioequivalent generic version of Relpax Tablets. The company has launched the product in two strengths, 20 mg and 40 mg tablets.

Eletriptan Hydrobromide Tablets is part of an ever growing portfolio of products that Ajanta has developed for the US market. In total, Ajanta has 35 Abbreviated New Drug Applications (ANDAs) of which it has 19 final ANDA approvals, 2 tentative approvals, and 14 ANDAs under review with US FDA. So far it has launched 14 products in the US market.

Ajanta Pharma is a speciality pharmaceutical formulation company having branded generic business in India and emerging markets, generic business in US and institution business in Africa.

Ajanta Pharma Share Price

2215.50 -2.45 (-0.11%)
02-May-2024 10:19 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1523.40
Dr. Reddys Lab 6244.05
Cipla 1413.05
Zydus Lifesciences 974.00
Lupin 1649.65
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.